Ok, so by the numbers you listed from the 10-K tha
Post# of 72440
That being said, given all the negative things that have occurred to the share price over the last 2 years, for CTIX to continue to complete clinical trials and progress the drugs at only 12% dilution seems like a pretty reasonable accomplishment to me. Am wrong on that? Is 12% dilution a high figure for a startup biotech company with so many mid-stage trials? I would not think so, but I am not as seasoned as others in this arena.
Comments or thoughts?